SCHEMBL7149872

SCHEMBL7149872

CCCCS(=O)(=O)N1C[C@@H](S)C[C@H]1C(=O)Nc1ccc(C(=O)OCC)cc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.52
GAA P10253 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
RAB9A P51151 5/20 0.49
ELOVL6 Q9H5J4 7/20 0.48
MAPT P10636 4/20 0.46
NPC1 O15118 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPK1 P28482 1/20 0.45
TP53 P04637 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7149870 1.00 ALDH1A1 (0.52) ALDH1A1GAASMN1; SMN2RAB9AELOVL6
SCHEMBL7142910 0.85 MAPT (0.62) ALDH1A1GAASMN1; SMN2RAB9AMAPT
SCHEMBL7143653 0.85 MAPT (0.62) ALDH1A1GAASMN1; SMN2RAB9AMAPT
SCHEMBL7141693 0.84 MMP1 (0.55) ALDH1A1GAASMN1; SMN2MAPTNPSR1
SCHEMBL7141699 0.84 MMP1 (0.55) ALDH1A1GAASMN1; SMN2MAPTNPSR1
SCHEMBL7139515 0.80 ALDH1A1 (0.59) ALDH1A1GAASMN1; SMN2MAPTNPSR1
SCHEMBL7139510 0.80 ALDH1A1 (0.59) ALDH1A1GAASMN1; SMN2MAPTNPSR1
SCHEMBL7150121 0.80 MME (0.46) ALDH1A1GAASMN1; SMN2RAB9AMAPT
SCHEMBL7145515 0.80 MAPT (0.58) ALDH1A1GAASMN1; SMN2RAB9AMAPT
SCHEMBL7144155 0.80 KMT2A (0.52) ALDH1A1GAASMN1; SMN2RAB9AELOVL6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885GAA 130/4885SMN1; SMN2 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.